Horsham, Pennsylvania — Clinical ink, a global life science technology company, today announced its second consecutive listing on the Deloitte Technology Fast 500, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28^th year. Clinical ink grew 241% during this period.

Clinical ink Chief Executive Officer, Ed Seguine, attributes the company’s dramatic growth to expertise in collecting clinical data in highly complex and diverse therapeutic areas including Alzheimer’s, Parkinson’s, Neurology, and Immunology, as well as innovations in eSource technology including sensors, voice, and digital biomarkers.

Seguine said, “At Clinical ink, we are committed to powering patient outcomes by converging data, technology, and patient science. This recognition demonstrates our significant industry impact, as well as our thriving partnerships with the trusted customers and patients we serve. In our industry, many private companies exaggerate financial performance. Our appearance on the respected Deloitte Technology Fast 500 for two straight years is direct evidence of our significant growth and financial performance.”

This is the second year in a row that Clinical ink has been ranked.

Now in its 28^th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2018 to 2021.

About the 2022 Deloitte Technology Fast 500

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Clinical ink  

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

The post Clinical ink Again Ranked Among Fastest-Growing Companies in North America on the 2022 Deloitte Technology Fast 500™ appeared first on Clinical ink.

Horsham, Pa.; August 15, 2022 — Clinical ink, a global life science technology company, has been named Clinical Trial Technology Partner of the Year by Corporate LiveWire, in their annual Innovation & Excellence Awards. The international award celebrates the success and achievements of companies that take an innovative approach to industry, and consistently show best practice in every aspect of their work. 

Over 90,000 businesses and corporate professionals nominated companies and individuals based on factors such as service, innovation, experience, sustainability, as well as other criteria. The research team at Corporate LiveWire narrowed and finalized the selection of awardees based on Clinical ink’s recent work in innovative data collection methods, including the deployment of sensors and wearables, as well as complex data analysis that employs machine learning to generate digital biomarkers—a game changer for the industry. 

Along with this recent Innovation & Excellence Award, in the past year, Clinical ink was awarded a spot on The Healthcare Technology Report’s Top 100 Healthcare Technology Companies, listed on 2021’s Deloitte Technology Fast 500 and nominated as Technology Company of the Year by the Philadelphia Alliance for Capital and Technologies (PACT), which celebrates the achievement and innovation of life sciences leaders. 

About Clinical ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.  

About CorporateLiveWire   

The Corporate LiveWire platform provides business professionals and individuals in the corporate sector with information on the latest news and developments from around the globe.

The post Clinical ink Named Clinical Trial Technology Partner of the Year appeared first on Clinical ink.

Horsham, Pa.; August 4, 2022 — Clinical ink, a global life science technology company, has been named a Top 100 Healthcare Technology Company of 2022 by The Healthcare Technology Report. From large pharmaceutical sponsors and genomics start-ups to innovative clinical data companies like Clinical ink, this year’s awardees are changing the face of the healthcare industry—leveraging considerable talent to find innovative solutions for healthcare’s most pressing issues. 

“We are honored to be named on this year’s Top 100 Healthcare Technology Company list,” said Clinical ink Chief Executive Officer Ed Seguine. “At Clinical ink, we are constantly working to power patient outcomes by converging data, technology, and patient science. This honor demonstrates the impact we’ve made in areas as diverse as Alzheimers, Parkinsons, Neuroscience, Immunology, and other complex conditions. Our latest innovations in digital sensors, voice, and decentralized trial functionality will continue to drive advancements in clinical discovery.”

The top 100 companies of 2022 represent a range of specialties, but the common thread is the impact they are having on patient lives, whether through direct treatment or by providing advanced, game-changing products and services. Among the key criteria considered were product or service quality, customer adoption, management team caliber, organizational effectiveness, and company growth—among other factors. 

Along with this award, in the past year, Clinical ink was listed on 2021’s Deloitte Technology Fast 500 and nominated as Technology Company of the Year by the Philadelphia Alliance for Capital and Technologies (PACT), which celebrates the achievement and innovation of life sciences leaders.

About Clinical ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.  

About The Healthcare Technology Report

The Healthcare Technology Report is your comprehensive source for business news, investment activity and corporate actions related to healthcare technology. We provide industry executives, professionals, and investors important news and information on the healthcare technology industry.

The post Clinical ink Named Top 100 Healthcare Technology Company of 2022 appeared first on Clinical ink.

Horsham, Pa. May 25, 2022 — Clinical ink, a global life science technology company, was nominated for Technology Company of the Year by the Philadelphia Alliance for Capital and Technologies (PACT) during the organization’s 29^th annual Enterprise Awards, held May 24, 2022. 

Clinical ink was recognized for pioneering and continually innovating direct data capture technologies, which allow for the measurement of clinical trial patients both in and outside the clinic. Notably, earlier in 2022 the company announced research that strengthens its standing as a critical partner in advancing clinical development for Parkinson’s disease, via the collection of patient data via sensors and at-home wearable assessments. 

Clinical ink was nominated by a panel of judges consisting of executives from the area’s largest life science and healthcare companies, healthcare and technology focused investors, and startup executives. 

“We are incredibly honored to be among the nominees,” says Chief Executive Officer Ed Seguine. “At Clinical ink, our work is rooted in enabling clinical discovery by bringing data, technology, and patient science together. We are proud to be recognized for our technological prowess, as well as our deep industry knowledge and scientific expertise. We will only continue to advance our offerings, ensuring that our partners can better power patient outcomes.” 

Over the past five years, Clinical ink has experienced 40% annual revenue growth. By consistently delivering technology solutions that allow for the collection of complex clinical data, the company has established relationships with the largest and most innovative pharmaceutical sponsors in the industry.  

About Clinical ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience. 

The post Clinical ink nominated for Technology Company of the Year by the Philadelphia Alliance for Capital and Technologies (PACT) appeared first on Clinical ink.

HORSHAM, Pa.; Nov. 17, 2021 (Business Wire) – Clinical Ink today announced it ranked on the Deloitte Technology Fast 500, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. Clinical Ink grew 293% during this period.

Clinical Ink’s Chief Executive Officer, Ed Seguine, credits the 293% growth to expertise in highly complex therapeutic areas (Alzheimers, Lupus, COVID) and novel execution models such as decentralized and remote trials. Seguine stated, “Clinical Ink has consistently delivered results for our customers and earned their trust. We’ve always been at the forefront of innovation with technologies that simplify and accelerate complex clinical trial activities. The recent acquisition of Digital Artefacts will drive future growth as we lead the next wave of innovation by simplifying the adoption of digital endpoints.”

About the 2021 Deloitte Technology Fast 500
Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

Clinical Ink ranked No. 393 on the Deloitte Technology Fast 500.

About Clinical Ink
Clinical Ink, a global clinical technology company, offers data certainty from source to submission. Our Lunexis eSource clinical technology and configurable direct data capture, eCOA, patient engagement, telehealth, eConsent, and instrumented data collection modules provide a suite of solutions for capturing and integrating electronic data from sites, clinicians, caregivers, and patients at its source. Clinical Ink’s therapeutic-area-specific approach to study design and data capture – with specific expertise in neurocognitive testing – enables more precise scales for cognitive and human factors assessments, including performance, behavior, movement, and all real-world activity.

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

The post Clinical Ink Ranked Among Fastest-Growing Company in North America on the Deloitte Technology Fast 500^TM appeared first on Clinical ink.

“After 20+ years of involvement with DIA, this moment only reignites my passion for changing the future of global health,” said Andrus. “It truly marks a renewed desire to continue to revolutionize clinical research with Clinical Ink’s future-built platforms and vision of eliminating paper source documents in clinical research.”

Like DIA’s mission to foster innovation and improve health and well-being worldwide, Clinical Ink is committed to dramatically reducing the cost and complexity of clinical research for sites, sponsors, and patients. Its pioneering EDC replacement, eCOA, and ePRO solutions are designed to support paperless clinical trials and make capturing, validating, and sharing data electronically both cleaner and faster, which ultimately helps accelerate new treatments to patients who need them.

Clinical Ink has completed over 200 studies — with experience in phase I, II, and III studies. Visit Andrus and the rest of the Clinical Ink team in Booth 2537 at DIA’s global, annual meeting to learn more about their EDC replacement, eCOA, and ePRO solutions.

Andrus will be delivering two presentations on Tuesday, June 25, at DIA’s global, annual meeting in San Diego, CA. At 2 p.m., he will join FDA and MHRA speakers to discuss: Electronic Systems: Are Yours Fit for Purpose? His 4:15 p.m. presentation is titled: Real World Evidence: How Does it Use Challenge Quality and Compliance Programs?  In this presentation, he will be joined by speakers from the FDA and the MHRA.

About Clinical Ink

Clinical Ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the company’s proven and future-built eSource platform, which includes solutions for EDC replacement, eCOA, ePRO, and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical Ink is advancing the business model responsible for bringing new treatments to market.

CONTACT:
Jane Byram
SCORR Marketing
512.626.2758
jane@scorrmarketing.com

The post Clinical Ink’s Jonathan R. Andrus Receives 2019 Inspire Award From DIA appeared first on Clinical ink.

“Our goal is to transform the entire rater experience with process-enabling technologies that lead to better assessments, so a partnership with the eSource pioneers at Clinical Ink was the clear choice for advancing that objective”, commented Cogstate CEO, Brad O’Connor. “This is one solution from two market leaders, so it is very much aligned to the ‘best-of-breed’ approach that many sponsors are taking for their outsourcing strategies; particularly in the area of CNS where signal detection is so challenging and endpoint quality assurance is so critical.”

“The benefits of eSource for CNS research are dramatic,” stated Ed Seguine, CEO, Clinical Ink. “Combining Cogstate’s therapeutic expertise with our SureSource® platform, which directly captures data in the moment during the patient visit, promises to improve protocol execution. Researchers can focus more attention on the patient and the ratings when workflow and scoring are automated. This is an incredible time for CNS research and Clinical Ink is delighted to partner with a therapeutic leader like Cogstate on this advancement.”

This joint solution delivers important advantages to sponsors seeking to transcend traditional paper-and-pencil assessment scales in their clinical trials, including:

• Custom edit checks, programmed workflows, and automated scoring at the point-of-care that prevent clerical errors and miscalculations
• Same day access to quality source data and documents for central monitoring by Cogstate’s network of local expert advisors (LEADs), with custom flagging algorithms designed by clinical scientists for rapid identification of rater variance
• Rater training that reaches beyond the investigator meeting and eLearning platforms by elegantly incorporating rater guidance directly into the rating scale instrument used during the patient visit for more accurate, standardized administration

A growing library of enhanced electronic scales ready for study-specific licensing and protocol customization
Key Learnings from a recent multi-site study will be presented in a live educational webinar, taking place November 9th at 11:00 a.m. EST.

About Cogstate

Cogstate Ltd (ASX:CGS) is a leading cognitive science company dedicated to simplifying the measurement of cognition in clinical trials, academic research and healthcare. Cogstate provides expert support for traditional neuropsychological and functional assessments to drive higher quality measures, and commercializes rapid, reliable and highly sensitive computerized cognitive tests. Cogstate customers include the world’s leading biopharmaceutical companies; military and elite sporting organizations; physicians and patients; renowned academic institutions and public-private partnerships.

Media Contact: Rachel Colite | 203.773.5010 | rcolite@cogstate.com

About Clinical Ink

Clinical Ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the Company’s proven and future-built eSource platform, which includes solutions for EDC replacement, eCOA, ePRO and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical Ink is advancing the business model responsible for bringing new treatments to market.

Media Contact: Jessica Romero | 336.728.6541 | jessica.romero@clinicalink.com

The post Cogstate and Clinical Ink Deliver Enhanced Tablet-Based eCOA for CNS Clinical Trials appeared first on Clinical ink.

Passionate about data management, Jonathan has helped grow the professional society on a global scale, including playing a major role in moving its headquarters from the US to Europe. Further, he has been instrumental in working with the society’s European, Indian, Chinese and Japanese members, supporting and growing activities in these regions with the aim of globally advancing data management.

At Clinical Ink, Jonathan focuses his initiatives on providing customers with the most compliant, efficient and quality-oriented products and services, stating, “Customer satisfaction is my number one priority and our entire company is united under the mission of providing our customers with the best possible experience by delivering a modern approach to clinical trial execution and data management.”

Congratulations to Jonathan for this tremendous recognition. Clinical Ink and the clinical trial data management industry are appreciative of your contributions to advancing clinical trial execution.

About Clinical Ink

Clinical Ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the Company’s proven and future-built CAPTURE platform, which includes solutions for EDC replacement, eCOA, ePRO and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical Ink is advancing the business model responsible for bringing new treatments to market. Visit clinicalink.com.

Media Contact: Jessica Romero | 336.728.6541 | jessica.romero@clinicalink.com

The post Clinical Ink’s COO & Chief Data Officer, Jonathan Andrus, Awarded SCDM Lifetime Achievement Award appeared first on Clinical ink.